Study of a drug for advanced solid tumors with MUC-1 marker
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug, M0324, alone or combined with pembrolizumab or chemotherapy, for advanced solid tumors that have a protein called MUC-1 on their surface. It may be an option for patients whose cancer has not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have an advanced or spreading solid tumor that makes too much of a protein called MUC-1.
- Your cancer must have stopped responding to standard treatments, or your doctor decides no standard treatment is right for you.
- If you join the pembrolizumab part, you must have already tried an immune checkpoint inhibitor and your cancer got worse while on it.
- If you join the chemotherapy part, you must have pancreatic cancer that hasn't been treated yet and be healthy enough for the chemotherapy regimen called mFOLFIRINOX. You cannot have had prior pancreatic surgery or chemotherapy.
- You must not have severe or ongoing diarrhea, inflammatory bowel disease, or a blockage in your intestines.
- You must not have had another cancer in the last 3 years, and your heart health must be good without uncontrolled high blood pressure or recent heart procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial studies OMTX705, given by itself or with an anti–PD-1 immune therapy, in people with advanced solid cancers that can’t be cured or that stopped responding to standard treatments. It aims to check safety and see whether the treatment can shrink tumors or control disease.
This Phase 1 trial studies a new experimental immunotherapy (MBS8) for people with advanced solid tumors, focusing first on safety and early signs of benefit. Depending on your cancer type and past treatments, you may receive MBS8 alone or combined with pembrolizumab.
This trial tests an oral medication called MOMA-341 in people with advanced solid tumors that have high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR). It aims to see if the drug can help when prior immunotherapy hasn't worked or isn't available.
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
This trial tests a new drug (BMS-986504) combined with standard chemotherapy or immunotherapy for three types of advanced solid tumors: mesothelioma, gastroesophageal cancer, or bladder cancer. It may be an option if your tumor has a specific genetic change called MTAP deletion.
This trial tests an experimental drug called M3T01, either alone or combined with pembrolizumab and other standard treatments, for people with advanced solid tumors or glioblastoma. The goal is to see if it is safe and effective.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.